The AMPK-Sirt1 pathway is an important regulator of energy metabolism and therefore a potential target for prevention and therapy of metabolic diseases. We recently demonstrated leucine and its metabolite β-hydroxy-β-methylbutyrate (HMB) to synergize with low-dose resveratrol (200 nM) to activate sirtuin signaling and stimulate energy metabolism. Here we show that leucine exerts a direct effect on Sirt1 kinetics, reducing its Km for NAD+ by >50% and enabling low doses of resveratrol to further activate the enzyme (p = 0.012). To test which structure elements of resveratrol are necessary for synergy, we assessed potential synergy of structurally similar and dissimilar polyphenols as well as other compounds converging on the same pathways with leucine using fatty acid oxidation (FAO) as screening tool. Dose-response curves for FAO were constructed and the highest non-effective dose (typically 1–10 nM) was used with either leucine (0.5 mM) or HMB (5 μM) to treat adipocytes and myotubes for 24 h. Significant synergy was detected for stilbenes with FAO increase in adipocytes by 60–70% (p<0.05) and in myotubes >2000% (p<0.01). Sirt1 and AMPK activities were stimulated by ~65% (p<0.001) and ~50% (p<0.03), respectively. Similarly, hydroxycinnamic acids and derivatives (chlorogenic, cinnamic, and ferulic acids) combined with leucine/HMB increased FAO (300–1300%, p<0.01), AMPK activity (50–150%, p<0.01), and Sirt1 activity (~70%, p<0.001). In contrast, more complex polyphenol structures, such as ellagic acid and epigallocatechin gallate required higher concentrations (>1 μM) and exhibited little or no synergy. Thus, the six-carbon ring structure bound to a carboxylic group seems to be a necessary element for leucine/HMB synergy with other stilbenes and hydroxycinnamic acids to stimulate AMPK/Sirt1 dependent FAO; these effects occur at concentrations that produce no independent effects and are readily achievable via oral administration.
References
[1]
Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712–716. doi: 10.1038/nature06261
[2]
Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, et al. (2009) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 29: 1363–1374. doi: 10.1128/mcb.00705-08
[3]
Canto C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20: 98–105. doi: 10.1097/mol.0b013e328328d0a4
[4]
Jager S, Handschin C, St-Pierre J, Spiegelman BM (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 104: 12017–12022. doi: 10.1073/pnas.0705070104
[5]
Brenmoehl J, Hoeflich A (2013) Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. Mitochondrion.
[6]
Timmer S, Auwerx J, Schrauwen P (2012) The journey of resveratrol from yeast to human. Aging (Albany NY) 4: 146–158.
[7]
Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, et al. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8: 157–168. doi: 10.1016/j.cmet.2008.06.011
[8]
Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 17187–17195. doi: 10.1074/jbc.m501250200
[9]
Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340–8351. doi: 10.1074/jbc.m109.088682
[10]
Hubbard BP, Gomes AP, Dai H, Li J, Case AW, et al. (2013) Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339: 1216–1219. doi: 10.1126/science.1231097
[11]
Park SJ, Ahmad F, Philp A, Baar K, Williams T, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421–433. doi: 10.1016/j.cell.2012.01.017
[12]
Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, et al. (2012) SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function. Cell Metab 15: 675–690. doi: 10.1016/j.cmet.2012.04.003
[13]
Bruckbauer A, Zemel MB (2011) Effects of dairy consumption on SIRT1 and mitochondrial biogenesis in adipocytes and muscle cells. Nutr Metab (Lond) 8: 91. doi: 10.1186/1743-7075-8-91
[14]
Bruckbauer A, Zemel MB, Thorpe T, Akula MR, Stuckey AC, et al. (2012) Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond) 9: 77. doi: 10.1186/1743-7075-9-77
[15]
Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, et al. (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8: 347–358. doi: 10.1016/j.cmet.2008.08.017
[16]
Nin V, Escande C, Chini CC, Giri S, Camacho-Pereira J, et al. (2012) Role of Deleted in Breast Cancer 1 (DBC1) Protein in SIRT1 Deacetylase Activation Induced by Protein Kinase A and AMP-activated Protein Kinase. J Biol Chem 287: 23489–23501. doi: 10.1074/jbc.m112.365874
[17]
Ong KW, Hsu A, Tan BK (2012) Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes. PLoS One 7: e32718. doi: 10.1371/journal.pone.0032718
[18]
Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, et al. (2010) Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol 48: 937–943. doi: 10.1016/j.fct.2010.01.003
[19]
Huang B, Yuan HD, Kim do Y, Quan HY, Chung SH (2011) Cinnamaldehyde prevents adipocyte differentiation and adipogenesis via regulation of peroxisome proliferator-activated receptor-gamma (PPARgamma) and AMP-activated protein kinase (AMPK) pathways. J Agric Food Chem 59: 3666–3673. doi: 10.1021/jf104814t
[20]
Kang W, Hong HJ, Guan J, Kim DG, Yang EJ, et al. (2012) Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 61: 424–433. doi: 10.1016/j.metabol.2011.08.003
[21]
Robich MP, Osipov RM, Chu LM, Han Y, Feng J, et al. (2011) Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol 664: 45–53. doi: 10.1016/j.ejphar.2011.04.059
[22]
Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, et al. (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106: 383–389. doi: 10.1017/s0007114511000316
[23]
Cho SJ, Jung UJ, Choi MS (2012) Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br J Nutr: 1–10.
[24]
D'Archivio M, Filesi C, Vari R, Scazzocchio B, Masella R (2010) Bioavailability of the polyphenols: status and controversies. Int J Mol Sci 11: 1321–1342. doi: 10.3390/ijms11041321
[25]
Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246–1252. doi: 10.1158/1055-9965.epi-07-0022
[26]
Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038–17045. doi: 10.1074/jbc.m500655200
[27]
Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, et al. (2012) A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One 7: e49761. doi: 10.1371/journal.pone.0049761
[28]
Manach C, Scalbert A, Morand C, Remesy C, Jimenez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79: 727–747.
[29]
Boswell-Smith V, Cazzola M, Page CP (2006) Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 117: 1237–1243. doi: 10.1016/j.jaci.2006.02.045
[30]
Baraldi PG, Tabrizi MA, Gessi S, Borea PA (2008) Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 108: 238–263. doi: 10.1021/cr0682195
Arner P, Hellmer J, Hagstrom-Toft E, Bolinder J (1993) Effect of phosphodiesterase inhibition with amrinone or theophylline on lipolysis and blood flow in human adipose tissue in vivo as measured with microdialysis. J Lipid Res 34: 1737–1743.
[33]
Zhang R, Maratos-Flier E, Flier JS (2009) Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 150: 3076–3082. doi: 10.1210/en.2009-0108
[34]
Sabatini S, Sgro P, Duranti G, Ceci R, Di Luigi L (2011) Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. Acta Biochim Pol 58: 237–241.
[35]
Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, et al. (2007) Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56: 1025–1033. doi: 10.2337/db06-0883
[36]
Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, et al. (2003) Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299: 896–899. doi: 10.1126/science.1079368
[37]
Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, et al. (2004) Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci U S A 101: 16507–16512. doi: 10.1073/pnas.0405432101
[38]
De Toni L, Strapazzon G, Gianesello L, Caretta N, Pilon C, et al. (2011) Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo. J Endocrinol Invest 34: 738–741. doi: 10.1007/bf03346724
[39]
Lira VA, Brown DL, Lira AK, Kavazis AN, Soltow QA, et al. (2010) Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol 588: 3551–3566. doi: 10.1113/jphysiol.2010.194035
[40]
Mitschke MM, Hoffmann LS, Gnad T, Scholz D, Kruithoff K, et al. (2013) Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J 27: 1621–1630. doi: 10.1096/fj.12-221580
